RecruitingDrug trialA Study to Evaluate DJI136, a DLL3-targeted CAR-T TherapyThis is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.